Recommendations about add-on reimbursement for medical devices in France in August 2022

08

Sep 2022

The French National Authority for Health released new recommendations about add-on reimbursement of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in August 2022. One recommendation was published in relation to the registration for devices in the List of reimbursable products and services. The opinion concerns men’s health area.

The first step in the assessment is the clinical (actual) benefit (SA), which can be either sufficient or insufficient. This step determines the insertion into the LPPR list. If sufficient, the clinical added value (ASA) is graded on a scale from I (major) to V (absent) for claimed indications, which supports the pricing decisions.

Only one recommendation was published, and it related to men’s health technology group: Absorbable synthetic hydrogel spacer for the prevention of rectal toxicity from curative external radiotherapy for prostate cancer in low-risk or intermediate-risk patients PACEOAR by BOSTON SCIENTIFIC (application for registration; sufficient actual benefit; level IV of clinical added value)

See the details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

21

Sep 2022

In September 2022, Ordering Forum for New Methods has invited interested parties regarding electric field therapy (Optune, Tumor Treating Fields) alone or in combination with drugs for certain groups of glioblastoma patients, based on genome sequencing and biomarkers (indication II). Information should be submitted before November 8, 2022. Ordering Forum will be held on November 21, 2022, to decide whether the method will undergo evaluation at the national level.

Read more

20

Sep 2022

In late August 2022, the updated version of the DRG tariff system guide (Takstsystem) was released by the Danish Health Data Agency (Sundhedsdatastyrelsen). No new DRGs were introduced in the updated version of the DRG tariff system guide. However, two new groups were added to the List of special services, for which supplementary payment may be charged.

Read more

19

Sep 2022

On September 1, 2022, the Institute for Hospital Remuneration Systems (INeK) announced the start of the application process according to §6 (2) KHEntgG (New Examination and Treatment Methods, NUB) for 2023. The deadline for the submission of applications is October 31, 2022.

Read more

14

Sep 2022

The French National Authority for Health (HAS) released new recommendations about transitional coverage of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in August 2022. One opinion was published regarding the cardiac resynchronization system WISE CRT-SYSTEM by EBR System.

Read more

06

Sep 2022

On August 11, 2022, NHS England and NHS Improvement released an updated National Genomic Test Directory for rare and inherited diseases (version 3.1), which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. No new codes (test-indication combinations) were introduced.

Read more